Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2017

View Archived Issues

Spring Bank announces latest results from phase II inarigivir study

Investigational mineralocorticoid receptor antagonist KBP-5074 evaluated in phase I trial

Seres Therapeutics announces collaboration to test its microbiome therapies in cancer patients

OncoArendi Therapeutics patents arginase inhibitors

Bayer discovers new vasopressin receptor antagonists

FDA approves Genentech's Gazyva in new indication

GlaxoSmithKline discloses novel EZH2 inhibitors

Shanghai De Novo Pharmatech has presented TLR8 agonists

Amgen presents novel apelin receptor agonists

Sutent now approved in U.S. as adjuvant treatment for adults at high risk of recurrent RCC

Bayer and PeptiDream establish drug discovery collaboration

Evelo Biosciences and Mayo Clinic enter monoclonal microbial collaboration

Deerfield Management and Johns Hopkins announce creation of Bluefield Innovations

NICE recommends routine funding for Ibrance and Kisqali in England

Bayer presents preclinical data on the cardiac effects of BAY-1142524 after myocardial infarction

bb-2121 receives FDA breakthrough therapy and EMA PRIME designations

NIH grant supports MRSA osteomyelitis research at University of Rochester

FDA first to approve Hemlibra for hemophilia A

Thetis Pharmaceuticals obtains NIH grant to support development of ulcerative colitis drug

Bayer reports first-in-human data for BR-6819

FDA issues alert regarding Takeda's febuxostat for gout

Alnylam Pharmaceuticals begins rolling NDA submission for patisiran

FDA approves new formulation and pediatric indication for Tekturna

PIN Pharma begins phase I study of immune-modulator in solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...